Printer Friendly

DOR BioPharma's GVHD treatment receives first European Orphan Medicinal Product designation.

Dor BioPharma, Inc., Chicago, IL, announced it has received its first Orphan Medicinal Product designation from the European Agency for the Evaluation of Medicinal Products (EMEA), the European drug regulatory agency, on its drug orBec for the treatment of intestinal Graft Versus Host Disease (GVHD). The Orphan drug designation in Europe adds to the previous similar designation in the US, where orBec also has an additional designation for prevention of GVHD.

The Orphan drug designation in Europe provides for a 10-year exclusive marketing period in all European Union member countries, full or partial exemption from product registration fees, and protocol and regulatory assistance from EMEA.

The company's orBec is currently under development in the US in a pivotal multicenter phase III trial to evaluate its efficacy for the treatment of iGVHD, a frequent complication of allogeneic bone marrow transplantation. The drug is also being evaluated for the treatment of other gastrointestinal disorders including a multicenter phase II trial in the US for Crohn's disease that affects an estimated 500,000 patients.

Contact: Colin Bier, PhD - (847) 573-8990
COPYRIGHT 2002 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:orBec, for treating intestinal Graft Versus Host disease
Comment:DOR BioPharma's GVHD treatment receives first European Orphan Medicinal Product designation.(orBec, for treating intestinal Graft Versus Host disease)
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 31, 2002
Words:177
Previous Article:Organogenesis receives FDA 510(k) clearance to market rotator cuff repair patch.
Next Article:MTF, Spineology enter into agreement on advanced bone graft technology.
Topics:


Related Articles
ARIAD's gene-target drug to treat graft-versus-host disease granted orphan drug status by the FDA.
ARIAD'S GENE-TARGETED DRUG GRANTED ORPHAN DRUG STATUS BY FDA.
Abgenix, SangStat receive orphan drug designation for acute GVHD treatment.
DOR BioPharma licenses irritable bowel syndrome patents.
DOR BioPharma reports orBec improves mortality rates in leukemia patients following bone marrow transplant.
DOR BioPharma completes enrollment in Phase III clinical trial for acute intestinal GVHD disease treatment.
DOR BIOPHARMA/CAMBREX ACHIEVE RIVAX MILESTONE.
DOR BioPharma and Dowpharma enter into a joint development agreement for oral vaccine against botulinum toxin poisoning.
DOR BioPharma receives not approvable letter from FDA for use of orBec for treating GHVD.
Osiris receives FDA fast track status for Prochymal in treat Crohn's disease; European approval for treating GVHD.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters